Drug Detail

Information about XL820

Generic Name
IND	XL820
Brand Name (US)
Manufacturer	Exelixis
Drug Type	Tyrosine Kinase Inhibitor
Delivery	Oral
Approval Status	Phase 2
Indications
Overall Strategy	KIT Protein Based
Strategy	Block KIT
Drug Category	KIT/PDGFRA inhibitor

XL820 is a novel small molecule inhibitor of the receptor tyrosine kinases KIT, VEGFR2, and PDGFR-α and -β. In preclinical studies, XL820 potently inhibited the resistance-associated activation loop mutations in KIT, and mutations in the ATP binding region of KIT including those in the juxtamembrane domain.

XL820 has been investigated in two Phase 1 studies (XL820-001 and XL820-002), and is being evaluated in a multi-center Phase 2 study (XL820-201) of subjects with advanced gastrointestinal stromal tumors (GIST) resistant to or intolerant of imatinib and/or sunitinib.

We understand the phase II trial has stopped and the trial status is "withdrawn".